NeoGenomics Launches RaDaR ST for MRD Detection Across Multiple Solid Tumors (neogenomics.com)

• Personalized ctDNA MRD panel for solid tumors
• Detection limit of 1 ppm with nearly 100% specificity
• Median lead time of 12.4 months in breast cancer, 154 days in head and neck cancer
• Medicare-approved and covered by over 300 insurance contracts

"NeoGenomics has introduced RaDaR ST, a personalized circulating tumor DNA (ctDNA) test for minimal residual disease (MRD) across multiple solid tumors. The test uses custom panels based on each patient's tumor profile, achieving a detection limit as low as 1 ppm with nearly 100% specificity. Clinical validation studies demonstrate a median lead time of 12.4 months in breast cancer and 154 days in head and neck cancer. The test is Medicare-approved for selected indications and covered by over 300 commercial insurance contracts."